Contact Us


Market Entry of Advanced Wound Care Products Set to Change Treatment Landscape

Over the next five years, the DFU market is expected to see significant changes. In the wound-healing segment of the market, Macrocure's CureXcell and Derma Sciences' DSC127 have the most favorable clinical attributes, as clinical trial data are already available for both drugs, from post-marketing studies involving CureXcell in Israel, where it is already marketed, and from a Phase II trial of DSC127. 
In terms of commercial attractiveness, KOLs interviewed by GlobalData believe that CureXcell is the most unique and promising of the late-stage pipeline agents currently in development.

News Archive

CureXcell, a cell based therapy for hard to heal wounds, to restore the wound healing process READ MORE

Hard to heal wounds are a growing problem for which there is currently
no available solution that satisfy unmet needs. Hard to heal wounds result in a significant morbidity and mortality, lengthened hospital stays, and a significant...  READ MORE

9 Bareket st. 
Petach Tikva, Israel

1- 700- 700 -241

contact us...  READ MORE

All rights reserved to MacroCure                        CureXcell is currently available for sale in Israel only

Simply-Smart |   |